Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 291.40K | 342.70K | 118.90K | 192.20K | 283.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 291.40K | 342.70K | 118.90K | 192.20K | 283.00K |
| Cost of Revenue | 224.70K | 269.30K | 379.90K | 434.60K | 438.90K |
| Gross Profit | 66.70K | 73.50K | -260.90K | -242.30K | -155.80K |
| SG&A Expenses | 1.07M | 1.08M | 1.47M | 1.66M | 1.39M |
| Depreciation & Amortization | 45.20K | 45.40K | 44.80K | 44.40K | 43.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.34M | 1.40M | 1.90M | 2.14M | 1.87M |
| Operating Income | -1.04M | -1.05M | -1.78M | -1.95M | -1.59M |
| Income Before Tax | 11.08M | 9.74M | 6.84M | -2.35M | -3.10M |
| Income Tax Expenses | 362.10K | 362.10K | 1.20M | -- | -- |
| Earnings from Continuing Operations | 10.72 | 9.38 | 5.64 | -2.35 | -3.10 |
| Earnings from Discontinued Operations | 1.13M | 1.13M | 8.78M | 8.00M | 8.26M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 75.20K | 45.10K | -37.20K |
| Net Income | 11.85M | 10.51M | 14.49M | 5.70M | 5.12M |
| EBIT | -1.04M | -1.05M | -1.78M | -1.95M | -1.59M |
| EBITDA | -998.40K | -1.01M | -1.73M | -1.90M | -1.55M |
| EPS Basic | 0.07 | 0.06 | 0.09 | 0.04 | 0.03 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | 0.07 | 0.06 | 0.09 | 0.04 | 0.03 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |